Incontinence-associated dermatitis Skin and Connective Tissue Diseases Dermatitis
Conditions
Interventions
The IAD Manual, developed during parts 1 and 2 of the study www.isrctn.com/ISRCTN26169429) will be implemented following the training of care staff and compared with usual care in care homes and home
Sponsors
King's College London
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Urinary and/or faecal incontinence with or without IAD receiving care at home from a home care agency or within a care home providing nursing and/or residential care 2. Capacity to give valid informed consent or declaration by personal or nominated consultee where resident’s capacity to give informed consent is lacking as defined under the Mental Capacity Act 2005 3. Relative of an adult with incontinence receiving care at home or as a care home resident 4. Care staff providing incontinence care employed by a care home or home care agency involved in the study
Exclusion criteria
Exclusion criteria: 1. Residents who are continent of both urine and feces 2. Personnel not involved in direct continence care such as work experience, volunteer and short-term agency staff
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Current primary outcome measure as of 17/10/2024: Incontinence-Associated Dermatitis presence and severity measured and recorded according to the core outcome set for IAD (erythema, maceration, erosion, pain and satisfaction) using Ghent Global Incontinence-Associated Dermatitis Categorisation Tool (GLOBIAD), Incontinence-Associated Dermatitis Intervention Tool (IADIT), Minimum Data Set (MDS) for IAD, Wong-Baker Faces Scale, Self-Assessment of Psoriasis Symptoms (SAPS), and the Hospital Anxiety and Depression Scale (HADs) at baseline, 3 and 6 months. Care staff from all six study sites will also use the Minimum Data Set (MDS) for IAD to collect weekly data from the recruited adults living in care homes and their own homes. _____ Previous primary outcome measure: Incontinence-Associated Dermatitis presence and severity measured and recorded according to the core outcome set for IAD (erythema, maceration, erosion, pain and satisfaction) using Ghent Global Incontinence-Associated Dermatitis Categorisation Tool (GLOBIAD), Incontinence-Associated Dermatitis Intervention Tool (IADIT), Wong-Baker Faces Scale and Self-Assessment of Psoriasis Symptoms (SAPS) at baseline, 3 and 6 months | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Recruitment rates/attrition will be assessed through investigator notes at 6 months 2. Intervention fidelity will be assessed through non-participant observation at 3 and 6 months 3. Acceptability of intervention will be assessed through qualitative interviews of care home staff, patients and carers at 6 months | — |
Countries
England, United Kingdom
Contacts
Public ContactSue Woodward
Outcome results
None listed